Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. - Test2 - elhamkhani - TriplyDB

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

http://www.wikidata.org/entity/Q34259412

about

Cardiovascular safety of anti-diabetic drugs Advances in the treatment of type 2 diabetes: impact of dulaglutide The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials The emerging role of oxylipins in thrombosis and diabetes Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011 Prescription of oral antidiabetic drugs in Tyrol - Data from the Tyrol diabetes registry 2012-2015 Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study Trends in Emergency Department Visit Rates for Hypoglycemia and Hyperglycemic Crisis among Adults with Diabetes, United States, 2006-2011.Insulin Therapy: A Personal Approach Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study Secular Trends in the Clinical Characteristics of Type 2 Diabetic Patients With Severe Hypoglycemia Between 2008 and 2013.Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study.Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study.Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes.The rising cost of diabetes care in the USA.Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials.Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability.Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.The TZD insulin sensitizer clue provides a new route into diabetes drug discovery.The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013.Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested?National trends in the treatment of diabetic nephropathy in the United States.Premixed insulin regimens in type 2 diabetes: pros.Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.Fenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model.Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD.Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening.Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.

P2860

Q26741082-09D7096D-E098-4C97-BB81-CD268CD625AA Q26746220-BBFFCEBA-3B5F-44CC-B263-1B928823D9CF Q26748870-E29B954C-EAA5-4B69-B908-300D7FEF994A Q26823893-0CF8AFDB-914E-47F7-9586-33A99D183280 Q26992979-E3FB90A6-44FA-4234-9922-FCA05FF78A4C Q26995462-0B045967-A17F-48C3-8847-5F14EEF0EEA4 Q28072381-E259FC6B-DF40-4B7C-A632-A98DD07A7AC0 Q28109335-39C608C2-0332-4FE6-9C20-66017C4F7259 Q31146511-40E84F21-BC0E-4774-B0F4-5AF248E107B6 Q34315432-FEE24425-8729-40E8-BDEE-FE94243CB8A6 Q34317618-BA93F071-92D5-4DE5-952B-F2918F657E4F Q35739808-7E617875-7B3F-4702-8B1E-3FB95053AD00 Q35856357-3149B65F-8DA6-48B9-93BB-4B3A5B0F682E Q36109894-00FDC9EF-426C-478D-911D-1623220924FE Q36275557-A66C1F88-6777-4D56-BA2C-DD92A015B4C8 Q37133799-7E6A3F39-E9B7-4E84-BDB7-DBFA08E60334 Q37233958-192A701D-C78A-4305-A390-FE1D2431E198 Q37327943-E3610EB3-997B-4917-8870-A9195D6BB87D Q37355883-155A8F41-2D38-4F32-9035-0F36ABFF5C02 Q37516034-84331825-AF58-4A14-9C24-BE877632A941 Q37737142-5E467891-94E2-4D36-B45C-91DFB778975F Q37737160-78E4B32E-D6DB-41DD-BF23-05D94239D299 Q38219234-2AC6F97F-E5FC-4F91-9841-88C21778CCDA Q38264376-0038B553-24EA-43B7-B0A4-7ED15A79F2E5 Q38266329-7BB0D0D8-71AD-4BB6-A425-47A7237E8667 Q38401198-4DDB30E0-15E0-4F3D-908C-F95CA5BD8938 Q38568342-D2EE4A3F-13C8-41BA-9C49-986E15D7D12D Q38602769-5505F6CE-4DA2-4C4D-94C5-F82ED4DB7381 Q38610829-65719B0A-07FD-4E2B-852B-306A4EF4BDCE Q38983533-D1C74A00-0F87-479E-9FA0-D0F9B5517B73 Q39360590-98A211A7-EE43-43EC-BBA8-90522AA1434A Q39969204-8E968901-8F39-4AE7-8497-813C68175067 Q40291569-41ED13BA-DB1F-40FA-A8E8-824A488CE65A Q40839083-E5C67F94-BA19-4E78-9FAA-873960C3AFBB Q40960309-50989A87-0CBE-45B5-843C-CE02D192DE41 Q42377473-13062BF3-EB51-4036-B83F-483C8A61C2C7 Q43540210-2AB8744B-9862-4A4F-8509-0C36CCD5859D Q44127740-4A52EC52-6E9A-47DD-8D0A-B4E2017CFB19 Q47150840-E8B8C4AD-DA91-40D3-82EC-BB5EC5A20CBC Q47195337-FBF5E8D1-1C95-4BFC-8BD0-EC466E5FC549

P2860

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

http://www.wikidata.org/entity/Q34259412

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@ast

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@en

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@nl

type

label

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@ast

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@en

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@nl

prefLabel

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@ast

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@en

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@nl

P1433

Q34259412-ED45C938-AFA3-4E54-AEA7-F53DFEC75D46

P1476

Q34259412-81185C60-CE7F-413D-9532-1B4F70050130

P2093

Q34259412-0F8BB438-9889-41E7-ABC0-7ED3091723CB

Q34259412-5057E21A-4506-46BF-B8E4-FA773A26F5AD

Q34259412-BC9E17F1-2ADE-44D9-98F4-8CE3745BD3A5

P2860

Q34259412-0B1B8DEB-D82B-4E47-B054-98AF7C175AFE

Q34259412-130707FE-BC27-44C0-A096-201180971AEC

Q34259412-1A439DBA-8B80-4E77-B6AD-9015A9B026D6

Q34259412-1B9C65EB-A840-407F-951A-CC3000DBAF73

Q34259412-24BE64AF-AFE2-42E8-A024-3A542221E280

Q34259412-26E0F8CB-28DC-4DC1-9FC1-4549BE62C9DB

Q34259412-2E8ECB31-F4B1-48EA-B726-25B04FB7770A

Q34259412-3B732066-714E-45A6-A21C-1C540A9B5FE9

Q34259412-4C8345F7-A2DE-4CCE-B0CB-AF8A364D375E

Q34259412-51010C1A-43FA-4BC2-ACC5-FC4B19FD398B

P304

Q34259412-1931E689-5391-4AB0-9396-0633292D917C

P31

Q34259412-20098619-7472-445B-A120-DF24145A7E3A

P356

Q34259412-B1A96306-B84B-480C-B4D6-2CE45465A5C1

P407

Q34259412-5AD7D2CC-1AD3-43CF-80A3-63DB6D95275A

P433

Q34259412-AFD7C2DE-8C32-46C8-91A0-8F06864D1788

P478

Q34259412-54AC7525-6674-4713-B8C7-5E402D61A85C

P50

Q34259412-1E4E7B9D-C1A1-4E80-80E5-012DEA9720F2

Q34259412-7ADA9F03-1BC7-441A-84C9-6E2EE5446F13

P577

Q34259412-BBA9D1DC-DFA1-4F8A-999E-D5165F1428BC

P5875

Q34259412-6A13B98E-FAEA-4E17-BAA3-F14E34EA1200

P698

Q34259412-58734E0A-1ACE-4117-B610-9B640CE3DC48

P921

Q34259412-1B887A5B-491C-4EA4-B3A1-16017DBC4A03

P932

Q34259412-DC0FEC29-CF5A-4303-864B-FA2BF0949332

P356

P1433

P1476

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

@en

P2093

David Nartey

http://www.w3.org/2001/XMLSchema#string

G Caleb Alexander

http://www.w3.org/2001/XMLSchema#string

Lydia W Turner

http://www.w3.org/2001/XMLSchema#string

P2860

Economic costs of diabetes in the U.S. in 2012

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

National trends in treatment of type 2 diabetes mellitus, 1994-2007

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

P304

985-992

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC13-2097

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Randall S Stafford

P577

2013-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258336482

http://www.w3.org/2001/XMLSchema#string

P698

24198301

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

4178325

http://www.w3.org/2001/XMLSchema#string